Sign up
Pharma Capital

REVA Medical launches third-generation bioresorbable scaffold

The commercial launch of Fantom Encore solidifies REVA’s technological lead in bioresorbable scaffolds.
heart
First Fantom Encore implanted in a post-market trial

REVA Medical Inc (ASX:RVA) has launched the Fantom Encore bioresorbable scaffold (BRS) and has completed the first implant in a post-market trial.

The implant procedure was performed by Dr Matthias Lutz at the Universitätsklinikum Schleswig-Holstein in Kiel, Germany.

Fantom Encore is a third-generation coronary BRS with a market-leading thin strut profile compared to other commercially available, CE Mark BRS.

The scaffold will be immediately available in all countries where REVA is currently selling its second-generation Fantom coronary BRS, including Germany, Switzerland, Austria, Belgium, the Netherlands, Luxembourg, Italy and Turkey.

REVA CEO Reggie Groves said: “The commercial launch of Fantom Encore solidifies REVA’s technological lead in bioresorbable scaffolds

“No other company has a thin strut profile, x-ray visible BRS.

“With a leading product and clinical data generated through the FANTOM clinical trials, we are positioned for success in the coronary BRS market.”

REVA’s post-market trial is a single arm trial to assess the continued safety and performance of Fantom and Fantom Encore.

The primary endpoint is target lesion failure (TLF) at 12 months and patients will be followed through five years.

The post-market trial is currently enrolling with a target of 1,500 patients at 50 to 100 European centres.



Register here to be notified of future RVA Company articles
View full RVA profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.